OCX-063 is under clinical development by OccuRx and currently in Phase I for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase I drugs for Non-Proliferative Diabetic Retinopathy (NPDR) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OCX-063’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OCX-063 is under development for the treatment of non-proliferative diabetic retinopathy, proliferative vitreoretinopathy, wet (neovascular / exudative) macular degeneration, diabetic nephropathy, chronic kidney disease and focal segmental glomerulosclerosis (FSGS). It is administered through oral route and formulated in the form of capsule.
OccuRx (OccuRx Pty) is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies. The company is headquartered in Melbourne, Victoria, Australia.
For a complete picture of OCX-063’s drug-specific PTSR and LoA scores, buy the report here.